Thiem, Alexander and Mashhadiakbar, Pegah and Cussigh, Christiane and Hassel, Jessica C. and Grimmelmann, Imke and Gutzmer, Ralf and Schlaak, Max and Heppt, Markus and Duecker, Pia and Huening, Svea and Schulmeyer, Lena and Schilling, Bastian and Haferkamp, Sebastian and Ziemer, Mirjana and Moritz, Rose K. C. and Hagelstein, Victoria and Terheyden, Patrick and Posch, Christian and Gaiser, Maria R. and Kropp, Peter and Emmert, Steffen and Mueller, Britta and Tietze, Julia K. (2023) Immune checkpoint inhibition and targeted therapy for melanoma: A patient-oriented cross-sectional comparative multicentre study. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 37 (5). pp. 884-893. ISSN 0926-9959, 1468-3083
Full text not available from this repository. (Request a copy)Abstract
BackgroundChoosing the adequate systemic treatment for melanoma is driven by clinical parameters and personal preferences. ObjectiveEvaluation of the impact of disease and treatment on the daily life of patients receiving systemic therapy for melanoma. MethodsA German-wide, cross-sectional comparative study was conducted at 13 specialized skin cancer centres from 08/2020 to 03/2021. A questionnaire was distributed to assess patients' perception of disease and symptoms, the impact of their current treatment on quality of life (QOL) and activities, adverse events (AEs), therapeutic visits, as well as believe in and satisfaction with their current systemic melanoma treatment. Patient-reported outcomes (PROs) were rated on a continuous numerical rating scale or selected from a given list. ResultsFour hundred and fourteen patients with systemic melanoma therapy were included. 359 (87%) received immune checkpoint inhibition (ICI) and 55 (13%) targeted therapy (TT). About 1/3 of patients were adjuvantly treated, the remaining because of unresectable/metastatic melanoma. In subgroup analyses, only in the adjuvant setting, TT patients reported a significant decrease in their treatment associated QOL compared to patients with ICI (p = 0.02). Patients with TT were 1.9 times more likely to report AEs than patients with ICI, a difference being significant just for the adjuvant setting (p = 0.01). ICI treatment intervals differed significantly between adjuvant and unresectable/metastatic setting (p = 0.04), though all patients, regardless of their specific ICI drug, evaluated their treatment frequency as adequate. TT patients with dabrafenib/trametinib (n = 37) or encorafenib/binimetinib (n = 15) did not differ regarding the strain of daily pill intake. Patients older than 63 years rated various PROs better than younger patients. ConclusionsPatients evaluated their treatment mainly positively. ICI might be preferred over TT regarding QOL and patient-reported AEs in the adjuvant setting. Older melanoma patients appeared to be less impacted by their disease and more satisfied with their treatment.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | QUALITY-OF-LIFE; REPORTED OUTCOMES; PATIENTS PTS; CANCER; PEMBROLIZUMAB; SATISFACTION; ONCOLOGY; 5-YEAR; |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Dermatologie und Venerologie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 05 Mar 2024 14:01 |
| Last Modified: | 05 Mar 2024 14:01 |
| URI: | https://pred.uni-regensburg.de/id/eprint/58700 |
Actions (login required)
 |
View Item |
